Compare NBN & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | SPTX |
|---|---|---|
| Founded | 1872 | N/A |
| Country | United States | United States |
| Employees | 234 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2026 |
| Metric | NBN | SPTX |
|---|---|---|
| Price | $131.95 | $21.82 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $130.50 | N/A |
| AVG Volume (30 Days) | 80.7K | ★ 118.4K |
| Earning Date | 04-27-2026 | N/A |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.77 | N/A |
| Revenue Next Year | $18.72 | N/A |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.75 | $17.59 |
| 52 Week High | $142.31 | $28.38 |
| Indicator | NBN | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 46.26 |
| Support Level | $127.84 | $18.72 |
| Resistance Level | $137.72 | $22.75 |
| Average True Range (ATR) | 3.23 | 2.12 |
| MACD | 0.50 | -0.30 |
| Stochastic Oscillator | 89.52 | 13.67 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The bank conducts its loan-related activities through two primary channels: the National Lending Division and the Small Business Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans; consumer loans; and small business administration loans, among others. Additionally, the bank provides telephone banking, online banking, mobile banking, and remote deposit capture services, and other banking products and services. The majority of its revenue is derived in the form of interest and dividends.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.